Skip to main content
SpringerLink
Log in

Polycystic Ovary Syndrome and Obesity

  • Chapter
Obesity

Abstract

Polycystic Ovary Syndrome (PCOS) is a common condition in reproductive-age women. PCOS is characterized by both reproductive dysfunction and hyperandrogenemia. Importantly, PCOS is also associated with metabolic aberrations, including insulin resistance. There is a strong association between obesity and PCOS, based on epidemiology, aetiology and genetics studies. Increased adiposity worsens insulin resistance (which in turn results in compensatory hyperinsulinemia, with associated pleiotropic effects) and disrupts steroid metabolism, further enhancing androgenicity. Through these mechanisms, weight-gain unmasks PCOS in those women who are genetically predisposed. Conversely, even modest weight-loss of just 5 % body weight in obese women with PCOS often results in clinically meaningful improvements in reproductive, hyperandrogenic and metabolic dysfunction. Given inextricable interlinks between PCOS and obesity, novel therapies that promote weight-loss, including activation of brown adipose tissue, remain perhaps our most promising future therapeutic options for obese women with PCOS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992;36(1):105–11.

    Article  CAS  Google Scholar 

  2. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80(9):2586–93.

    CAS  PubMed  Google Scholar 

  3. Taponen S, Martikainen H, Jarvelin MR, Laitinen J, Pouta A, Hartikainen AL, et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab. 2003;88(1):141–7.

    Article  CAS  PubMed  Google Scholar 

  4. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2006;65(2):137–45.

    Article  CAS  Google Scholar 

  5. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434–8.

    CAS  PubMed  Google Scholar 

  6. Legro RS. The genetics of obesity. Lessons for polycystic ovary syndrome. Ann N Y Acad Sci. 2000;900:193–202.

    Article  CAS  PubMed  Google Scholar 

  7. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10(8):2107–11.

    CAS  PubMed  Google Scholar 

  8. Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon. 2014;14(11):e23235.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Barber TM, McCarthy MI, Franks S, Wass JA. Metabolic syndrome in polycystic ovary syndrome. Endokrynol Pol. 2007;58(1):34–41.

    PubMed  Google Scholar 

  10. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000;52(5):595–600.

    Article  CAS  Google Scholar 

  11. Barber TM, Bennett AJ, Groves CJ, Sovio U, Ruokonen A, Martikainen H, et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia. 2008;51(7):1153–8.

    Article  CAS  PubMed  Google Scholar 

  12. Ehrmann DA. Metabolic dysfunction in pcos: relationship to obstructive sleep apnea. Steroids. 2012;77(4):290–4.

    Article  CAS  PubMed  Google Scholar 

  13. Nitsche K, Ehrmann DA. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2010;24(5):717–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6):724–6.

    Article  CAS  PubMed  Google Scholar 

  16. Li T, Wu K, You L, Xing X, Wang P, Cui L, et al. Common variant rs9939609 in gene FTO confers risk to polycystic ovary syndrome. PLoS One. 2013;8(7):e66250.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, et al. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One. 2011;6(1):e16390.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Yan Q, Hong J, Gu W, Zhang Y, Liu Q, Su Y, et al. Association of the common rs9939609 variant of FTO gene with polycystic ovary syndrome in Chinese women. Endocrine. 2009;36(3):377–82.

    Article  CAS  PubMed  Google Scholar 

  19. Walley AJ, Blakemore AI, Froguel P. Genetics of obesity and the prediction of risk for health. Hum Mol Genet. 2006;15(Spec No 2):R124–30.

    Article  CAS  PubMed  Google Scholar 

  20. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100–4.

    Article  CAS  PubMed  Google Scholar 

  21. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853–61.

    Article  CAS  PubMed  Google Scholar 

  22. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.

    Article  CAS  PubMed  Google Scholar 

  23. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–74.

    Article  CAS  PubMed  Google Scholar 

  24. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.

    CAS  PubMed  Google Scholar 

  25. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res. 2001;56:295–308.

    Article  CAS  PubMed  Google Scholar 

  26. Nestler JE, Strauss 3rd JF. Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am. 1991;20(4):807–23.

    CAS  PubMed  Google Scholar 

  27. Franks S, White D, Willis D. Mechanisms of anovulation in polycystic ovary syndrome. In: Filicori M, Flamigni C, editors. The ovary: regulation, dysfunction and treatment. Amsterdam: Elsevier; 1996.

    Google Scholar 

  28. White D, Leigh A, Wilson C, Donaldson A, Franks S. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1995;42(5):475–81.

    Article  CAS  Google Scholar 

  29. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000;15(6):1266–74.

    Article  CAS  PubMed  Google Scholar 

  30. Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf). 1993;39(3):351–5.

    Article  CAS  Google Scholar 

  31. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab. 1998;83(11):3984–91.

    CAS  PubMed  Google Scholar 

  32. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–32.

    CAS  PubMed  Google Scholar 

  33. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005;51(6):931–8.

    Article  CAS  PubMed  Google Scholar 

  34. Adashi EY, Hsueh AJ, Yen SS. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology. 1981;108(4):1441–9.

    Article  CAS  PubMed  Google Scholar 

  35. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72(1):83–9.

    Article  CAS  PubMed  Google Scholar 

  36. Yki-Jarvinen H, Makimattila S, Utriainen T, Rutanen EM. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab. 1995;80(11):3227–32.

    CAS  PubMed  Google Scholar 

  37. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105(3):311–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Rice S, Christoforidis N, Gadd C, Nikolaou D, Seyani L, Donaldson A, et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod. 2005;20(2):373–81.

    Article  CAS  PubMed  Google Scholar 

  39. Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, et al. Increased 5{alpha}-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(9):3558–66.

    Article  CAS  PubMed  Google Scholar 

  40. Barber TM, Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373(1–2):68–76.

    Article  CAS  PubMed  Google Scholar 

  41. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15(3):297–307.

    Article  CAS  PubMed  Google Scholar 

  42. Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol. 2008;284(1–2):38–45.

    Article  CAS  PubMed  Google Scholar 

  43. Iniguez G, Torrealba IM, Avila A, Cassorla F, Codner E. Adiponectin serum levels and their relationships to androgen concentrations and ovarian volume during puberty in girls with type 1 diabetes mellitus. Horm Res. 2008;70(2):112–7.

    Article  CAS  PubMed  Google Scholar 

  44. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279(13):12152–62.

    Article  CAS  PubMed  Google Scholar 

  45. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94(4):e27–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Barber TM, Hazell M, Christodoulides C, Golding SJ, Alvey C, Burling K, et al. Serum levels of retinol-binding protein 4 and adiponectin in women with polycystic ovary syndrome: associations with visceral fat but no evidence for fat mass-independent effects on pathogenesis in this condition. J Clin Endocrinol Metab. 2008;93(7):2859–65.

    Article  CAS  PubMed  Google Scholar 

  47. Yildiz BO, Bozdag G, Otegen U, Harmanci A, Boynukalin K, Vural Z, et al. Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS. Reprod Biomed Online. 2010;20(1):150–5.

    Article  CAS  PubMed  Google Scholar 

  48. Cekmez F, Cekmez Y, Pirgon O, Emre Canpolat F, Aydinoz S, Metin Ipcioglu O, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 2011;22(1):32–7.

    CAS  PubMed  Google Scholar 

  49. Dikmen E, Tarkun I, Canturk Z, Cetinarslan B. Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol. 2011;27(7):475–9.

    Article  CAS  PubMed  Google Scholar 

  50. Jongwutiwes T, Lertvikool S, Leelaphiwat S, Rattanasiri S, Jultanmas R, Weerakiet S. Serum visfatin in Asian women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(8):536–42.

    Article  CAS  PubMed  Google Scholar 

  51. Munir I, Yen HW, Baruth T, Tarkowski R, Azziz R, Magoffin DA, et al. Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(8):4852–7.

    Article  CAS  PubMed  Google Scholar 

  52. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.

    Article  Google Scholar 

  53. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66(4):513–7.

    CAS  Google Scholar 

  54. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligo-anovulation with Polycystic Ovaries (PCO) but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006;91(10):3922–7.

    Article  CAS  PubMed  Google Scholar 

  55. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210–7.

    Article  CAS  PubMed  Google Scholar 

  56. Ciftci CF, Uckuyu A, Karadeli E, Turhan E, Toprak E, Ozcimen EE. Phenotypic subgroups of polycystic ovary syndrome have different intra-renal resistance symptoms. Ginekol Pol. 2012;83(12):910–5.

    PubMed  Google Scholar 

  57. Vaggopoulos V, Trakakis E, Chrelias C, Panagopoulos P, Basios G, Makridima S, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. J Endocrinol Invest. 2013;36(7):478–84.

    CAS  PubMed  Google Scholar 

  58. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006;91(12):4842–8.

    Article  CAS  PubMed  Google Scholar 

  59. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(4):E628–37.

    Article  CAS  PubMed  Google Scholar 

  60. Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009;116(12):1633–9.

    Article  CAS  PubMed  Google Scholar 

  61. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84(1):137–44.

    CAS  PubMed  Google Scholar 

  62. Marks SJ, Moore NR, Clark ML, Strauss BJ, Hockaday TD. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res. 1996;4(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  63. Zhuang XF, Zhao MM, Weng CL, Sun NL. Adipocytokines: a bridge connecting obesity and insulin resistance. Med Hypotheses. 2009;73(6):981–5.

    Article  CAS  PubMed  Google Scholar 

  64. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18(7):266–72.

    Article  CAS  PubMed  Google Scholar 

  65. Horejsi R, Moller R, Rackl S, Giuliani A, Freytag U, Crailsheim K, et al. Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. Am J Phys Anthropol. 2004;124(3):275–81.

    Article  CAS  PubMed  Google Scholar 

  66. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2003;79(6):1358–64.

    Article  PubMed  Google Scholar 

  67. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001;16(6):1255–60.

    Article  CAS  PubMed  Google Scholar 

  68. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab. 2005;90(11):6014–21.

    Article  CAS  PubMed  Google Scholar 

  69. Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, et al. Global adiposity rather than abnormal regional fat distribution characterises women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(3):999–1004.

    Article  CAS  PubMed  Google Scholar 

  70. Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96(2):E304–11.

    Article  CAS  PubMed  Google Scholar 

  71. Dolfing JG, Stassen CM, van Haard PM, Wolffenbuttel BH, Schweitzer DH. Comparison of MRI-assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS. Hum Reprod. 2011;26(6):1495–500.

    Article  CAS  PubMed  Google Scholar 

  72. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007;92(7):2500–5.

    Article  CAS  PubMed  Google Scholar 

  73. Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(2 Pt 1):380–9.

    Article  CAS  PubMed  Google Scholar 

  74. Mirshahi M, Ayani E, Nicolas C, Golestaneh N, Ferrari P, Valamanesh F, et al. The blockade of mineralocorticoid hormone signaling provokes dramatic teratogenesis in cultured rat embryos. Int J Toxicol. 2002;21(3):191–9.

    Article  CAS  PubMed  Google Scholar 

  75. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.

    Article  CAS  PubMed  Google Scholar 

  76. Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013;113(4):520–45.

    Article  PubMed  Google Scholar 

  77. Bates GW, Legro RS. Longterm management of Polycystic Ovarian Syndrome (PCOS). Mol Cell Endocrinol. 2013;373(1–2):91–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Jakicic JM, Tate DF, Lang W, Davis KK, Polzien K, Neiberg RH, et al. Objective physical activity and weight loss in adults: the step-up randomized clinical trial. Obesity (Silver Spring). 2014;22(11):2284–92.

    Article  Google Scholar 

  79. Klimczak D, Szlendak-Sauer K, Radowicki S. Depression in relation to biochemical parameters and age in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2015;184:43–7.

    Article  CAS  PubMed  Google Scholar 

  80. Bozdag G, Yildiz BO. Interventions for the metabolic dysfunction in polycystic ovary syndrome. Steroids. 2013;78(8):777–81.

    Article  CAS  PubMed  Google Scholar 

  81. Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine. 2013;44(3):583–90.

    Article  CAS  PubMed  Google Scholar 

  82. Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne). 2014;5:140.

    Google Scholar 

  83. Poher AL, Altirriba J, Veyrat-Durebex C, Rohner-Jeanrenaud F. Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance. Front Physiol. 2015;6:4.

    Article  PubMed Central  PubMed  Google Scholar 

  84. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360(15):1509–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360(15):1518–25.

    Article  CAS  PubMed  Google Scholar 

  86. Reddy NL, Jones TA, Wayte SC, Adesanya O, Sankar S, Yeo YC, et al. Identification of brown adipose tissue using MR imaging in a human adult with histological and immunohistochemical confirmation. J Clin Endocrinol Metab. 2014;99(1):E117–21.

    Article  PubMed  Google Scholar 

  87. Barber TM, Franks S. Genetic basis of polycystic ovary syndrome. Expert Rev Endocrinol Metab. 2010;5(4):549–61.

    Article  CAS  Google Scholar 

  88. Sorensen AE, Wissing ML, Salo S, Englund AL, Dalgaard LT. MicroRNAs related to Polycystic Ovary Syndrome (PCOS). Genes (Basel). 2014;5(3):684–708.

    Article  Google Scholar 

  89. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003;14(8):365–70.

    Article  CAS  PubMed  Google Scholar 

  90. Sanchez N. A life course perspective on polycystic ovary syndrome. Int J Womens Health. 2014;6:115–22.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflicting Interests and Financial Disclosure

The authors have nothing to declare.

Author information

Authors and Affiliations

  1. Division of Translational and Systems Medicine, Warwick Medical School, The University of Warwick, Clinical Sciences Research Laboratories, University Hospitals Coventry and Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX, UK

    Thomas M. Barber MA Hons, FHEA, FRCP, DPhil & George K. Dimitriadis MD, MSc (Hons)

  2. Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals Coventry and Warwickshire, Clifford Bridge Road, Coventry, CV2 2DX, UK

    Thomas M. Barber MA Hons, FHEA, FRCP, DPhil & George K. Dimitriadis MD, MSc (Hons)

  3. Institute of Reproductive and Developmental Biology, Imperial College, London, UK

    Stephen Franks MD, Hon MD, FRCP, FMedSci

Authors
  1. Thomas M. Barber MA Hons, FHEA, FRCP, DPhil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George K. Dimitriadis MD, MSc (Hons)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen Franks MD, Hon MD, FRCP, FMedSci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas M. Barber MA Hons, FHEA, FRCP, DPhil .

Editor information

Editors and Affiliations

  1. School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom

    Shamim I. Ahmad

  2. Al Mouwasat Hospital, Jubail, Saudi Arabia

    Syed Khalid Imam

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Barber, T.M., Dimitriadis, G.K., Franks, S. (2016). Polycystic Ovary Syndrome and Obesity. In: Ahmad, S., Imam, S. (eds) Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-19821-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19821-7_15

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19820-0

  • Online ISBN: 978-3-319-19821-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation